BenevolentAI

The biomedical Knowledge Graph and the reasoning built on it are the company. The disclosed method is specific: a network of contextualized scientific data covering genes, proteins, diseases and compounds and the relationships between them, normalized from literature, patents, genetics, chemistry and clinical trials, with machine learning finding connections between known facts and AI based reasoning extrapolating connections not previously stated anywhere. That is a claim no database or literature search product could make, and the company's platform enhancements have consistently been model work, including a next generation Knowledge Graph powered by natural language processing and large language models introduced to predict novel targets from scientific literature.

The oversight structure is the strongest disclosed in this category, and it is external rather than self certified. Targets predicted by the platform do not count as delivered until AstraZeneca has independently experimentally validated them and selected them for portfolio entry, a gate the partner controls and the vendor cannot grade itself against. Company and partner scientists are described as working side by side to frame and test hypotheses, and knowledge generated in the disease programmes is fed back to improve subsequent predictions. Held at B rather than A only because no internal confidence thresholds or published prediction reliability figures were located, so what a buyer can rely on is the strength of the external gate rather than a disclosed internal standard.

Substantially more detailed than most, helped by years as a listed company that required describing platform work to investors. Disclosed specifics include the composition and normalization approach of the Knowledge Graph, the introduction of a next generation graph powered by natural language processing, the adoption of large language models to predict therapeutic targets from literature, target identification tools extended to targets best prosecuted via alternative modalities, and a distinct product for target progressibility assessment covering druggability, selectivity and competitor and patent landscape. Held at B because no peer reviewed methods paper establishing platform predictive performance was located, and because the delisting has ended the reporting stream that produced most of this detail, so the disclosure is comprehensive but increasingly historical.

The most externally adjudicated evidence record in this category, and it earns the grade on independence rather than volume. Multiple novel targets discovered on the platform were experimentally validated by AstraZeneca and selected into its drug discovery portfolio across idiopathic pulmonary fibrosis, chronic kidney disease, systemic lupus erythematosus and heart failure, over a collaboration running from 2019 through at least 2024, which means a large pharmaceutical company repeatedly put its own laboratory resource behind the predictions and repeatedly confirmed them. Separately the platform first identified baricitinib as a COVID-19 treatment, which subsequently received FDA approval, and no other vendor in this category can point to an approved medicine traceable to a platform prediction, though buyers should note this was repurposing of an existing molecule rather than de novo discovery. Candour is equally strong: BEN-2293 was stopped after Phase IIa with the company stating plainly it would not invest further, so the failures are on the record alongside the wins.

Not applicable in the provider sense and rated accordingly rather than penalized. The Knowledge Graph is assembled from published literature, patents, genetics, chemistry and clinical trial data together with licensed and partner contributed datasets, not from identifiable patient records. Worth noting that AstraZeneca's proprietary genomics, chemistry and clinical data was integrated into the graph under that collaboration, so the stewardship question that arises is partner data governance rather than PHI.

Not applicable. The company is a United Kingdom based research organization contracting with pharmaceutical partners rather than a business associate of covered entities handling protected health information.

No SOC 2, ISO 27001 or equivalent attestation was located and no trust center was found. The relevant exposure is partner data: AstraZeneca integrated proprietary genomics, chemistry and clinical data into the Knowledge Graph, so a partner's diligence on this axis runs through the collaboration agreement. The 2025 transition to private ownership removes the listed company control and reporting environment that previously provided indirect assurance.

Correctly structured, with the platform not presented as a regulated device and regulatory activity at the asset level. Disclosed programmes have moved through real regulatory steps: BEN-2293 completed a Phase IIa study in atopic dermatitis before being discontinued, BEN-8744 for ulcerative colitis progressed from clinical trial application to a Phase I trial, BEN-28010 was declared a clinical candidate, and BEN-34712 for ALS was described as in IND enabling work. Buyers should treat the published pipeline as historical unless a newer table is issued, since the company is now private and the 2024 restructuring prioritized five assets and shifted strategy toward partnering earlier stage programmes.

No AI governance framework or bias disclosure was located. The domain relevant question is sharper here than for any other vendor in this category because of what the platform is built from: a Knowledge Graph assembled largely from published scientific literature inherits publication bias directly, so well studied biology is densely represented while understudied diseases, understudied populations and negative results are thin or absent. A system that extrapolates novel connections from that substrate will find more in the areas science has already crowded into. The company's use of literature normalization and large language models addresses extraction quality rather than what is missing from the corpus, and no analysis of coverage or representativeness was located.

Not applicable. This is a target identification and discovery platform with no provider workflow surface and no EHR touchpoint. Integration effort is directed at normalizing heterogeneous scientific and partner datasets into the Knowledge Graph.

Historically not applicable, since the platform was operated in house and delivered through collaboration with scientists working side by side rather than as software deployed to a customer, and no tenancy, hosting or residency terms were located. The December 2024 strategy statement is forward looking and worth tracking: the company said it intends to transform its existing technology into more flexible standalone product offerings enabling faster integration and customised applications. If that materializes the axis becomes assessable, but nothing shipped was identified in this review.

This grade records a change of state rather than an act of concealment, and the trajectory is the point. As a listed company BenevolentAI disclosed more than almost anyone in this category, publishing a three pillar monetisation model covering end to end discovery partnerships, the clinical and preclinical pipeline and knowledge exploration products, along with detailed platform progress, target delivery counts and adverse pipeline decisions. That reporting stream ended with the 13 March 2025 delisting from Euronext Amsterdam, executed as a merger into Osaka Holdings after which the original entity ceased to exist and the acquiring Luxembourg vehicle took the BenevolentAI name. The company is now private, no pricing or current deal economics were located, and a buyer evaluating it today is working from a disclosure record that stops in early 2025.

Disease agnostic by design and demonstrated across an unusually wide indication range for this category, with disclosed work in idiopathic pulmonary fibrosis, chronic kidney disease, systemic lupus erythematosus, heart failure, atopic dermatitis, ulcerative colitis, ALS and COVID-19 repurposing. Target identification is also described as extending to targets best prosecuted via alternative modalities rather than being locked to small molecules. Held at B rather than A because the 2023 pipeline review narrowed the portfolio to five prioritized assets and the 2024 restructuring reduced scope further, so demonstrated breadth is historical while current capacity is smaller than the record implies. Buyers should ask what the platform is resourced to cover now rather than what it has covered.